Reimagine Medicine | Novartis United States of America

Media Release
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Media Release
Oct 02, 2019
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Media Release
Dec 09, 2019
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Media Release
Nov 15, 2019
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Media Release
Nov 13, 2019
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
Media Release
Feb 11, 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Media Release
Jan 16, 2020
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Media Release
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Media Release
Mar 28, 2020
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Media Release
Jun 03, 2021
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Media Release
Apr 06, 2022
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Media Release
Mar 24, 2022
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer